Distilling compliance lessons from healthcare fraud cases
By 
Jaclyn Jaeger2019-01-24T10:00:00
False Claims Act recoveries related to healthcare fraud in fiscal year 2018 offer key insight into the best practices the government expects to ensure compliance with federal healthcare laws.
Related articles
-
Article
An inside look at False Claims Act enforcement
Deputy Associate Attorney General Stephen Cox in remarks this week offered some key insight into the Department of Justice’s enforcement principles, policies, and perspectives that guide its False Claims Act enforcement.
-
ArticleSanctions, money-laundering and supply chains top agenda for energy sector compliance
The energy sector faces rising regulatory activity, with more rules and enforcement. Bribery, corruption, and sanctions now dominate compliance concerns, driving rapid change and pressure on compliance officers.
-
ArticleSenate Democrats question Vought on comments about closing CFPB in months
Senate Democrats warned OMB Director Russell Vought Tuesday that it would be illegal for the Trump administration to shut down the Consumer Financial Protection Bureau, citing a recent court decision barring actions that could severely harm the agency.
More from Regulatory Enforcement
-
News BriefCFPB ends probe into Meta’s financial advertising practices
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
-
News BriefTexas sues Johnson & Johnson, Kenvue over alleged misleading marketing of Tylenol
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.
-
News BriefCFPB scraps bad-actor registry, citing cost-benefit issues
The Consumer Financial Protection Bureau shut down a registry of non-bank financial firms that broke consumer laws. The agency cites the costs being ”not justified by the speculative and unquantified benefits to consumers.”